Breaking News

ProBioGen, Abcuro Ink GlymaxX Pact

ProBioGen to provide cell line development leveraging its CHO.RiGHT expression platform through to GMP production

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ProBioGen AG, a service and technology provider for complex therapeutic antibodies and glycoproteins, has signed a services and license agreement with Abcuro, Inc. Pursuing a new generation of immune modulatory bio-therapeutics, Abcuro has developed a new first in class antibody for autoimmunity and oncology indications. ProBioGen will conduct the full service package from cell line development using its CHO.RiGHT expression platform over process development until GMP manufacturing. Since kil...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters